ATE371454T1 - Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie - Google Patents

Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie

Info

Publication number
ATE371454T1
ATE371454T1 AT02772562T AT02772562T ATE371454T1 AT E371454 T1 ATE371454 T1 AT E371454T1 AT 02772562 T AT02772562 T AT 02772562T AT 02772562 T AT02772562 T AT 02772562T AT E371454 T1 ATE371454 T1 AT E371454T1
Authority
AT
Austria
Prior art keywords
menorrhagia
prostaglandin
antagonists
receptors
treatment
Prior art date
Application number
AT02772562T
Other languages
English (en)
Inventor
Henry Jabbour
Hilary Critchley
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26246719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE371454(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0126094A external-priority patent/GB0126094D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Application granted granted Critical
Publication of ATE371454T1 publication Critical patent/ATE371454T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02772562T 2001-10-31 2002-10-28 Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie ATE371454T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0126094A GB0126094D0 (en) 2001-10-31 2001-10-31 Method of treatment
US40286402P 2002-08-09 2002-08-09

Publications (1)

Publication Number Publication Date
ATE371454T1 true ATE371454T1 (de) 2007-09-15

Family

ID=26246719

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772562T ATE371454T1 (de) 2001-10-31 2002-10-28 Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie

Country Status (9)

Country Link
US (2) US20050059742A1 (de)
EP (1) EP1450813B1 (de)
JP (1) JP2005511562A (de)
AR (1) AR037164A1 (de)
AT (1) ATE371454T1 (de)
DE (1) DE60222168T2 (de)
ES (1) ES2292814T3 (de)
TW (1) TW200303194A (de)
WO (1) WO2003037348A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090088400A1 (en) 2007-09-11 2009-04-02 Puymirat Jack Prostaglandin e2 modulation and uses thereof
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2392323A4 (de) 2009-01-30 2012-09-26 Univ Kyoto Progressionshemmer für prostatakrebs und verfahren zur progressionshemmung
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
PT3113774T (pt) 2014-03-06 2022-02-28 Elanco Animal Health Incorporated Composições de grapiprant e métodos de utilização das mesmas
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US6197993B1 (en) * 1996-07-02 2001-03-06 Ono Pharmaceutical Co., Ltd. Naphthyloxyacetic acid derivatives and a pharmaceutical composition comprising them as an active ingredient
US5912006A (en) * 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6586468B1 (en) * 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
US6211221B1 (en) * 1999-04-05 2001-04-03 Johnny W. Peterson Dietary supplement containing histidine for alleviating dysmenorrhea, endometriosis, and pre-term labor
AU6836200A (en) * 1999-08-10 2001-03-05 Glaxo Group Limited Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer
MXPA02005626A (es) * 1999-12-06 2004-09-10 Pital Sainte Justine H Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.
CA2402099C (en) * 2000-03-24 2011-04-26 Pharmagene Laboratories Ltd. Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment
GB0124124D0 (en) * 2001-10-08 2001-11-28 Medical Res Council Methods of treatment
US20030220266A1 (en) * 2001-10-30 2003-11-27 Sales Kurt Jason Method of treating a disease

Also Published As

Publication number Publication date
EP1450813B1 (de) 2007-08-29
DE60222168D1 (de) 2007-10-11
DE60222168T2 (de) 2008-05-15
AR037164A1 (es) 2004-10-27
TW200303194A (en) 2003-09-01
US20050059742A1 (en) 2005-03-17
US20080206309A1 (en) 2008-08-28
WO2003037348A1 (en) 2003-05-08
EP1450813A1 (de) 2004-09-01
ES2292814T3 (es) 2008-03-16
JP2005511562A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
ATE371454T1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60221798D1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
DE60335743D1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60028358D1 (de) Hmg1 antagonisten zur behandlung von entzündungen
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE250575T1 (de) Ep4 rezeptor selektive agonisten zur behandlung der osteoporose
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE311200T1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
DE60228317D1 (de) N-aryl-n'-arylcycloalkyl-harnstoff als mch antagonisten zur behandlung von fettleibigkeit
DE69913548D1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60228567D1 (de) Behandlung von hyperlipidämie
DE60129330D1 (de) Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties